Vistagen's fasedienol achieves ICH E1 minimum safety exposure recommendations

Vistagen announced its fasedienol nasal spray program for social anxiety disorder has met international safety database exposure standards with over 1,500 subjects enrolled. The milestone supports the company's path toward potential NDA submission, with Phase 3 PALISADE-4 topline results expected in Q2 2026.